CCS
INVA icon

Crosspoint Capital Strategies’s Innoviva INVA Stock Holding History

Crosspoint Capital Strategies’s Portfolio INVA Stock Details INVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-150
Closed -$2K – 621
2014
Q4 		$2K Buy
+150
New +$2.25K ﹤0.01% 675

Other funds holding INVA

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
PC
Perry Capital New York $334M AUM 8.27% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CPM
Chesapeake Partners Management Baltimore, Maryland $669M AUM 1.23% 1-Year Est. Return
LM
Litespeed Management New York $48.2M AUM 9.81% 1-Year Est. Return

Crosspoint Capital Strategies's INVA Position: Q1 2015 in Review

Crosspoint Capital Strategies sold out of Innoviva (INVA) in Q1 2015, closing a stake of 150 shares — an estimated $2K sold.

Crosspoint Capital Strategies first reported a position in INVA in Q4 2014 and held it in 1 quarter. The position peaked at $2K in Q4 2014. 110 funds tracked by Wall St. Rank hold INVA as of Q1 2015.

  • Crosspoint Capital Strategies reported no remaining Innoviva position as of Q1 2015 after selling out during the quarter.
  • Crosspoint Capital Strategies sold 150 Innoviva shares in Q1 2015, an estimated $2K.
  • Crosspoint Capital Strategies first reported a position in Innoviva in Q4 2014 and held it in 1 quarter.
  • Crosspoint Capital Strategies's Innoviva position peaked at $2K in Q4 2014.
  • 110 funds tracked by Wall St. Rank held Innoviva as of Q1 2015.

Based on Crosspoint Capital Strategies's 13F filing for Q1 2015, filed 18 May 2015.